In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects

Acta Anaesthesiologica Scandinavica

Volumn 41, Issue 8, 1997, Pages 955-966

  Ording H ^v   Brancadoro, V ^a   Cozzolino, S ^b   Ellis, F R ^c   Glauber, V ^d   Gonano, E F ^e   Halsall, P J ^c   Hartung, E ^f   Heffron, J J A ^g   Heytens, L ^h   Kozak Ribbens, G ⁱ   Kress, H ^j   Krivosic Horber, R ^k   Lehmann Horn, F ^l   Mortier, W ^m   Nivoche, Y ⁿ   Ranklev Twetman, E ^o   Sigurdsson, S ^p   Snoeck, M ^q   Stieglitz, P ^r   Tegazzin, V ^s   Urwyler, A ^t   Wappler, F ^u   more..

^a Department of Anaesthesiology ^*  (Italy)

^b Servizio Epidemiologico   (Italy)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d SHEBA MEDICAL CENTER   (Israel)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g UNIVERSITY COLLEGE CORK   (Ireland)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ University of Aix Marseille   (France)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY OF ULM   (Germany)

^m Klinikum Wuppertal   (Germany)

ⁿ HÔPITAL ROBERT DEBRÉ   (France)

^o LUND UNIVERSITY HOSPITAL   (Sweden)

^p REYKJAVIK UNIVERSITY   (Iceland)

^q RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^r GRENOBLE UNIVERSITY HOSPITAL   (France)

^s Traumatologic Orthopedic Hospital   (Italy)

^t UNIVERSITY HOSPITAL BASEL   (Switzerland)

^u UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^v UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Anesthesia; Caffeine; Complication; Diagnosis; Halothane; Inhalational; Malignant hyperthermia; Ryanodine receptor

Indexed keywords

CAFFEINE; HALOTHANE; RYANODINE RECEPTOR;

ADOLESCENT; ADULT; AGED; ANESTHESIA COMPLICATION; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN; HUMAN TISSUE; INHALATION ANESTHESIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTHERMIA; MUSCLE TWITCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROVOCATION TEST; SCHOOL CHILD;

EID: 9844240499     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1997.tb04820.x     Document Type: Article

References (28)

1. European MH Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984: 56: 1267-1269.
2. European MH Group. Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). Br J Anaesth 1985: 57: 1038.
3. Larach MG. Standardization of the halothane caffeine muscle contracture test. Anesth Analg 1989: 69: 511-515.
4. Ørding H. Investigation of malignant hyperthermia in Denmark. Dan Med Bull 1996: 43: 111-125.
5. Hartung E, Sold M, Preis I. Diagnostik der Malignen Hyperthermie: Ein Vergleich des Halothan-Muskel-Kontrakturtestes nach dem Europäischen und dem Nordamerikanischen Protokoll. Anaesthesist 1990: 39: 635.
6. Riegelman RK, Hirsch RP. Studying a study and testing a test. How to read the medical literature, 2nd edn. Boston: Little, Brown and Company, 1989: 151-163.
7. Ørding H. The European MH Group: protocol for in vitro diagnosis of susceptibility to MH and preliminary results. In: Britt BA, ed. Malignant hyperthermia. Boston: Martinus Nijhoff Publishing, 1987: 269-277.
8. Hartung E. Die Bedeutung des Pflanzenalkaloids Ryanodin für die Diagnostik der Malignen Hyperthermie. Würzburg: University Press, 1996: 55-61.
9. Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993: 79: 5-9.
10. Wedel DJ, Nelson TE. Malignant hyperthermia - diagnostic dilemma: false-negative contracture responses with halothane and caffeine alone. Anesth Analg 1994: 78: 787-792.
11. Ørding H, Hedengran AM, Skovgaard LT. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol Scand 1991: 35: 711-716.
12. Allen GC, Rosenberg H, Fletcher JE. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility. Anesthesiology 1990: 72: 619-622.
13. Islander G, Ranklev-Twetman E. Evaluation of anaesthesias in malignant hyperthermia negative patients. Acta Anaesthesiol Scand 1995: 39: 819-821.
14. Heytens L, Martin JJ, van de Keift E, Bossaert LL. In vitro contracture tests in patients with various neuromuscular diseases. Br J Anaesth 1992: 68: 72-75.
15. Halsall PJ, Cain PA, Ellis FR. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized. Br J Anaesth 1979: 51: 949-954.
16. Bendixen D, Skovgaard LT, Ørding H. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesthesiol Scand 1997: 41: 480-484.
17. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994: 80: 771-779.
18. Ellis FR, Harriman DGF. A new screening test for susceptibility to malignant hyperpyrexia. Br J Anaesth 1973: 45: 638-639.
19. Ranklev E, Fletcher R, Blomquist S. Static versus dynamic in vitro tests in the diagnosis of malignant hyperthermia susceptibility. Br J Anaesth 1986: 58: 646-648.
20. Ørding H, Skovgaard LT. In vitro diagnosis of susceptibility to malignant hyperthermia: comparison between dynamic and static halothane and caffeine tests. Acta Anaesthesiol Scand 1987: 31: 458-461.
21. Ricker K, Moxley III RT, Heine R, Lehmann-Horn F. Myotonia fluctuans: A third type of muscle sodium channel disease. Arch Neural 1994: 51: 1095-1102.
22. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970: 17: 293-315.
23. Bendixen D, Poulsen TD, Knudsen F, Nielsen J, Ørding H. Clinical variability of possible malignant hyperthermia as revealed by two cases. Acta Anaesthesiol Belg 1994: 45: 93-98.
24. Larach MG, Landis JR, Shirk SJ, Diaz M, The North American Malignant Hyperthermia Registry. Prediction of malignant hyperthermia susceptibility in man: improving sensitivity of the caffeine halothane contracture test. Anesthesiology 1992: 77: A1052.
25. Larach MG, Landis JR, Bunn JS, Diaz M, The North American Malignant Hyperthermia Registry. Prediction of malignant hyperthermia susceptibility in low-risk subjects. Anesthesiology 1992: 76: 16-27.
26. Quane KA, Kearing KE, Manning BM, Healy JMS, Monsieurs K, Heffron JJA et al. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum Mol Genet 1994: 3: 471-476.
27. Keating KE, Quane KA, Manning BM, Lehane M, Hartung E, Censier K et al. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum Mol Genet 1994: 3: 1855-1858.
28. Healy JMS, Quane KA, Keating KE, Lehane M, Heffron JJA, McCarthy TV. Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree. J Med Genet 1996: 33: 18-24.